As of May 14, 2020, the World Health Organization has reported 4,248,386 cases of COVID-19 with 294,046 reported deaths secondary to complications related to the novel Coronavirus [1]. In the United States, the Center for Disease Control (CDC) reported 1,364,061 total cases and 82,246 COVID-19 related deaths [2]. A common complication reported secondary to COVID-19 is Acute Respiratory Distress Syndrome (ARDS) requiring endotracheal intubation and ventilator management. Experts currently believe that ARDS possibly results from a state of hyper-inflammation mediated by a cytokine storm in COVID-19 patients [3]. Recipients of solid organ transplants are included in a special population of patients who may face increased risks of COVID-19 related complications given their use of chronic immunosuppressants. Immunosuppression in this population can further reduce cell-mediated immunity, which may prolong viral shedding and increase the risk of COVID related complications [3]. As reported by McGonagle et al., interleukin-6 (IL-6) plays an important role in lung repair following viral insults and the administration of IL-6 inhibitor drugs may be time-sensitive [3]. We report a case of COVID-19 in a patient with kidney and liver transplant and discuss the use of IL-6 inhibitor to prevent a cytokine storm in this setting.